Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
15.75    0.00 (0.00%)
Bid:
15.50
Ask:
16.00
Spread: 0.50 (3.226%)
Market Cap: £13.00m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Fundraising for portfolio company, Nandi

3 Nov 2014 07:00

RNS Number : 8874V
Frontier IP Group plc
03 November 2014
 



 

AIM: FIPP

 

Frontier IP Group plc

("Frontier IP" or "the Company")

 

Nandi Proteins Limited - Fundraising

 

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce that its portfolio company, Nandi Proteins Limited ("Nandi"), has completed a funding round totalling £660,000 (gross). The round comprises capital from new shareholders of £575,000 and existing debt conversion totalling £85,000. New investors include Parkwalk Technology Funds and Quilter Cheviot Limited.

 

As part of the funding round, Frontier IP has converted part of the debt owed to it by Nandi into 3,738 Nandi shares, bringing Frontier IP's total shareholding in Nandi to 21.49%. Following this investment round, the Company's holding in Nandi has been revalued and shows an uplift of over £0.3m. The revaluation will be recognised in Frontier IP's Annual Report & Financial Statements for the year ended 30 June 2014.

 

The new funding provides working capital to enable Nandi to support the roll-out of its technology to its food industry customers and partners, increase its scientific resource and continue to protect and develop its intellectual property portfolio. The investment will also enable Nandi to exploit further certain glycation technologies previously licensed to Tate & Lyle plc and now reverted to Nandi.

 

Nandi, spun out of Heriot Watt University Edinburgh, develops patented technology which improves the functional properties of common proteins in food and beverage applications. Nandi is focused on food industry and ingredients customers for whom its technology provides a range of benefits including lower cost, reduced fat and sugar and clean labelling with no e-numbers.

 

Interest in Nandi's technology is increasing, in particular with the drive to tackle obesity and other weight-related problems combined with government-led initiatives such as traffic-light food labelling, which is leading the food industry to explore new ways of reducing fats and sugars in product. Nandi's technology has potential application in a wide range of proteins used in the food industry, with the total global protein ingredient market size estimated at $10 billion (Source: UBIC Consulting Report 2014).

 

Neil Crabb, Chief Executive of Frontier IP, said,

 

"Nandi is at an important stage in its development with its innovative protein technology now at the point of roll-out. I am delighted with the strong support we received for this funding round, which reflects Nandi's very encouraging prospects."

 

Michael Brennand, Executive Chairman of Nandi, said,

 

"This funding will enable us to work closely with our partners to take our products into the food ingredient marketplace. With the increasing concern over obesity, our technology has significant relevance to food producers looking at how they can reduce fats and sugars in their products without compromising the taste experience."

 

 

Enquiries

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

Mark Percy / Catherine Leftley, Corporate Finance

David Banks / Paul Jewell, Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Jon Levinson / Lucy Williams

KTZ Communications

T: 020 3178 6378

Katie Tzouliadis / Deborah Walter

 

Trade Enquiries

 

Nandi Proteins Limited

Michael Brennand

T: 07966 341801

Executive Chairman

 

 

 

Notes to Editor:

 

Frontier IP Group plc ("Frontier IP") specialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes. www.frontierip.co.uk.

 

Nandi Proteins Limited ("Nandi") is a sales, marketing, IP and licensing company spun out of Heriot Watt University, Edinburgh. The company develops patented process technology and know how to improve the functional properties of common proteins such as whey, egg and soy. The company's objective is to become a market leader in the field of denatured protein technology.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGMMFGVMFGDZM
Date   Source Headline
6th Jul 20267:00 amRNS-RInSignals Neurotech Grant
30th Jun 20265:00 pmRNSTotal Voting Rights
26th Jun 202610:03 amRNSHolding(s) in Company
25th Jun 20262:44 pmRNSHolding(s) in Company
25th Jun 20267:00 amRNSHolding(s) in Company
24th Jun 20267:00 amRNS-RPortfolio news: Investment in Fieldwork Robotics
23rd Jun 20267:00 amRNSPosting of Circular and Notice of General Meeting
19th Jun 20267:00 amRNSResult of Retail Offer
17th Jun 20267:00 amRNSResult of Placing and Subscription
16th Jun 20265:20 pmRNSRetail Offer
16th Jun 20264:58 pmRNSProposed Placing and Subscription
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.